Pharmaceutical products

Tender description

Offer reference number: CM/PHR/16/5521 CM/PHR/16/5521/01 — NHS Framework for the NHS South of England, Branded Medicines – tranche A, period of framework: 1.9.2019 to 31.8.2021 with an option to extend (at the authority’s discretion) for a period or periods up to a total of 24 months CM/PHR/16/5521/02 — NHS Framework for the NHS South of England, Branded Medicines – annual tranche — cytokine modulators and other monoclonal antibodies, period of framework: 1.9.2019 to 31.8.2020 with an option to extend (at the authority’s discretion) for a period or periods up to a total of 12 months. CM/PHR/16/5521/03 — NHS Framework Agreement for Proprietary Pharmaceuticals Interim 2019 – Midlands and East and North of England, period of framework agreement: Midlands and East 1.9.2019 to 29.2.2020: North of England 1.9.2019 to 28.2.2021. CM/PHR/16/5521/01 — NHS Framework for the NHS South of England, Branded Medicines – tranche A, period of framework: 1.9.2019 to 31.8.2021 with an option to extend (at the authority’s discretion) for a period or periods up to a total of 24 months. CM/PHR/16/5521/02 — NHS Framework for the NHS South of England, Branded Medicines – annual tranche — cytokine modulators and other monoclonal antibodies, period of framework: 1.9.2019 to 31.8.2020 with an option to extend (at the authority’s discretion) for a period or periods up to a total of 12 months. CM/PHR/16/5521/03 — NHS Framework Agreement for Proprietary Pharmaceuticals Interim 2019 — Midlands and East and North of England, period of framework agreement: Midlands and East 1.9.2019 to 29.2.2020: North of England 1.9.2019 to 28.2.2021.